BBIO

BridgeBio Pharma (BBIO)

BridgeBio Pharma Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:BBIO

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/06/04	20:30	GlobeNewswire Inc.	BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/06/04	05:01	GlobeNewswire Inc.	BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/05/30	05:01	GlobeNewswire Inc.	Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/05/24	20:30	GlobeNewswire Inc.	BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/05/18	05:09	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/05/15	20:30	GlobeNewswire Inc.	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/05/14	20:30	GlobeNewswire Inc.	BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/05/13	20:30	GlobeNewswire Inc.	BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensiti	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/05/02	20:30	GlobeNewswire Inc.	BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/05/02	20:00	GlobeNewswire Inc.	BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/04/10	20:30	GlobeNewswire Inc.	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/04/08	02:15	GlobeNewswire Inc.	BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/03/20	20:30	GlobeNewswire Inc.	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/03/07	07:15	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/03/07	07:13	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/03/06	13:53	GlobeNewswire Inc.	BridgeBio Pharma Announces Pricing of Public Offering of Common Stock	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/03/05	07:25	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/03/05	06:17	GlobeNewswire Inc.	BridgeBio Pharma Announces Proposed Public Offering of Common Stock	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/03/04	21:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/03/04	16:30	GlobeNewswire Inc.	BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/02/23	06:27	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/02/22	21:31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/02/22	21:30	GlobeNewswire Inc.	BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/02/22	06:04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/02/21	06:03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/02/16	06:06	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/02/14	06:05	Edgar (US Regulatory)	Form 5 - Annual statement of changes in beneficial ownership of securities	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/02/14	06:00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/02/07	21:34	GlobeNewswire Inc.	BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan	NASDAQ:BBIO	BridgeBio Pharma Inc
2024/02/06	21:30	GlobeNewswire Inc.	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BBIO	BridgeBio Pharma Inc